The rapid development of fundamental and applied molecular biology area in oncology, huge array of biomedical and pharmacological data, knowledge (big data) and software capabilities to process them, there is a real possibility of clinical interpretation of genomic data arrays of cancer patients. The company operates with a dedicated interactive service ONCOGENE® , providing to medical oncologists possibility of clinical interpretation of the genomic profile of solid malignant tumor of patients to support the best clinical decision-making when selecting potentially effective and safe protocols on anticancer drug treatment.
Medical reports are generated using a diagnostic device (software) MH Guide® (CE-IVD), registered in Europe, which is intended for clinical interpretation of genomic data of patient's tumor, and obtained as a result of whole-exome sequencing of DNA tumor. MH Guide® is associated with Dataome® – the world’s largest cloud technology platform (proprietary knowledge base), intended for collection, processing, integration and analysis of the structured and unstructured world medical, biological and pharmacological data with the highest quality, amount, diversities, novelty, relevance, safety and utility in real time.
In this context, a local conference was held in Chisinau, November, 13th under the theme „The role of genetics in medicine: A future of precision medicine”. It was attended by around 40 oncologists and pathologists. Prof. Matthias Löhr has presented the clinical application of MHGuide ® and its role in the decision-making process for cancer patients, Karolinska Institutet, Sweden.
During the presentation Prof. Matthias Löhr highlighted the role of personalized medicine and molecular diagnostics in clinical practice and the evaluation of characteristics of MHGuide® Report. As well were presented specific requirements for a tumor sample. Afterwards, Molecular Health overview was presented by Dr. Miguel Cordova, Application Specialist Scientific Sales Support. These presentations opened the floor for a highly interactive discussion between the oncologists and Prof. Matthias Löhr who shared his personal clinical experience.
Such an exchange of experience left moldavian oncologists more confident in what should a medical oncologist focus on when choosing targeted therapy, given that genomic profiling is a promising perspective in cancer management.
The company Oncogene SRL (Chisinau, Republic of Moldova) is an official and exclusive partner of Molecular Health GmbH in: